In human patients, drugs that block tumor vessel growth are widely used to treat a variety of cancer types. Many rigorous phase 3 clinical trials have demonstrated significant survival benefits; however, the addition of an anti-angiogenic component to conventional therapeutic modalities has generally produced modest survival benefits for cancer patients. Currently, it is unclear why these clinically available drugs targeting the same angiogenic pathways produce dissimilar effects in preclinical models and human patients. In this article, we discuss possible mechanisms of various anti-angiogenic drugs and the future development of optimized treatment regimens.
CITATION STYLE
Cao, Y. (2016, February 15). Future options of anti-angiogenic cancer therapy. Chinese Journal of Cancer. Landes Bioscience. https://doi.org/10.1186/s40880-016-0084-4
Mendeley helps you to discover research relevant for your work.